about RenalytixAI

RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally.  RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

RenalytixAI’s technology platform will draw from distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.

In 2019, RenalytixAI expects to launch KidneyIntelXTM, an artificial intelligence in vitro diagnostic product intended to support physician decision making by improving identification, prediction, and risk stratification of patients with progressive kidney disease.

RenalytixAI considers there to be a significant opportunity to deliver quality-assured, regulated, AI-driven product for the chronic kidney disease (CKD) market.

A costly disease

The International Society of Nephrology estimates that over 850 million people worldwide have some form of kidney disease, approximately twice that of diabetes (422 million) and 20 times more than cancer.  By this estimate, kidney disease affects 10.4% of men and 11.8% of women worldwide.

In the US, CKD affects over 40 million adults and kills more people than breast or prostate cancer. Commonly referred to as a “silent disease” kidney disease is often asymptomatic until a majority of kidney function has been lost.  As a result, CKD is associated with significant morbidity, mortality and healthcare costs.

It is estimated that a third of adults in the US are at risk of kidney disease. This risk is greatest for those suffering from diabetes, high blood pressure, heart disease and obesity. Studies have also shown that ethnicity is a determining factor, with African Americans and Hispanic populations deemed most at risk.

latest News

17Oct

RenalytixAI Partners with Capital District Physicians’ Health Plan, Inc. on KidneyIntelX™

Renalytix AI plc, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that Capital District Physicians’ Health Plan, Inc. .. Read More →
14Oct

Johns Hopkins Director of Nephrology Chirag Parikh Joins RenalytixAI Board

Renalytix AI plc announces the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board... Read More →
01Oct

US CPT® reimbursement code effective for KidneyIntelX™

RenalytixAI plc announces CPT reimbursement code 0105U for its KidneyIntelX™ test in the United States.. Read More →